Clinical trials have shown the successful use of intranasal insulin to safely improve memory and cognition in patients with mild cognitive impairment or Alzheimer’s disease without alteration in the blood levels of insulin or glucose [3, 27]. This evidence concerns the gene INS and early-onset autosomal dominant Alzheimer disease.